Immutep (IMMP) announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint. The novel combination significantly exceeded the study’s prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma. Tumour hyalinization/fibrosis is an early surrogate endpoint at the time of surgical resection that has been associated with improved overall survival and recurrence-free survival for STS patients. The trial’s investigators at the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, plan to present detailed results from the study at a future medical meeting.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep’s Promising Phase 1 INSIGHT-003 Results Drive Buy Rating
- Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial
- Immutep announces response rates from INSIGHT-003 trial
- Biotech Alert: Searches spiking for these stocks today
- Immutep’s Promising Phase 2b Results and Strong Financial Position Justify Buy Rating